Amgen Inc reported second-quarter 2026 results with revenue of $10.05B and diluted EPS of $4.37, versus $9.18B and $2.65 in the year-ago quarter, driven by product sales growth and stronger demand for several key medicines.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$10.05B$9.18B9.5% | Net income²$2.38B$1.43B65.9% | Diluted EPS³$4.37$2.6564.9% |
¹ Reported as “Total revenues”. ² Reported as “Net income”. ³ Reported as “Diluted earnings per share”.
Business Highlights
- Revenue growth was driven by product sales (+9%) and other revenues (+27%), supporting overall top-line expansion of about 10% for the quarter.
- U.S. and rest-of-world volumes rose roughly 9% and 8% respectively, although net selling price declines and policy actions (including IRA, 340B and MFN) continued to pressure margins.
- Strong performance from Repatha, EVENITY, TEZSPIRE, UPLIZNA and IMDELLTRA/IMDYLLTRA helped offset accelerated erosion of Prolia and XGEVA due to biosimilars.
- Operational progress included EU approval for IMDYLLTRA in ES‑SCLC based on positive Phase 3 survival data and ongoing capital investments to expand manufacturing capacity.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.